Vaxcyte Inc (PCVX)

$30.25 -0.20 (-0.66%)
Market Cap 3.95B
Revenue (ttm) 0.00
Net Income (ttm) -463.93M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,859,600
Avg Vol 1,418,724
Day's Range N/A - N/A
Shares Out 129.82M
Stochastic %K 7%
Beta 1.21
Analysts Strong Sell
Price Target $114.88

Company Profile

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conju...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 837 0111
Website: vaxcyte.com
Address:
825 Industrial Road, Suite 300, San Carlos, United States
justiceforb_85
justiceforb_85 Aug. 8 at 1:00 AM
$PCVX look forward to VAX-31 entering the clinic. Company with significant cash reserve but timeline in long.
0 · Reply
OptionRunners
OptionRunners Aug. 7 at 3:05 PM
$PCVX Buyer of the December 19th $30 calls 1,000 times for $4.80-$4.90 Buying into this earnings sell off
0 · Reply
d_risk
d_risk Aug. 7 at 1:15 AM
$PCVX - Vaxcyte Inc. Common Stock - 10Q - Updated Risk Factors PCVX’s 10-Q risk update spotlights pipeline shifts with paused/discontinued candidates, intensified focus on VAX-31 Phase 3, expanded regulatory and manufacturing complexities, evolving ACIP guidelines, heightened financial losses, and new risks around data variability, AI use, cybersecurity, global trials, IP litigation, and ESG compliance—all amid a challenging competitive and policy landscape. #Biotechnology #Cybersecurity #FinancialRisk #RegulatoryCompliance #VaccineDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/PCVX/10-Q/2025-08-06
0 · Reply
joe77w
joe77w Aug. 1 at 3:10 AM
$STRO $PCVX $EXEL worth more dead than alice, STRO worth at least 2.5usd if liquidate imo
1 · Reply
mmqwerty00
mmqwerty00 Aug. 1 at 2:26 AM
$STRO Jane needs to not be a hero. Preclinical molecules with no Phase 1 expansion data until 2027 - spread way too thin. Need to use her head, announce "strategic alternatives" and the stock goes to $1.50 overnight. Stick a 250M asking price on it - go to $PCVX or $EXEL and try and sell the whole thing - they give you 180M-200M in current market, you say thanks and call it a day. Puts stock around 2-2.50/share. The dilution that will eventually be needed to do anything of value would be catastrophic. Know the hand you are holding. Trying to take 3 preclinical molecules into clinic with just 18-24 months of cash, your stock price at all time lows and a biotech market where trying to use meaningful capital will get you demolished? Literally would be insanity. Lets hope they are smarter than this dumb guy who can see this clearly and figure it out
0 · Reply
Icarus81
Icarus81 Jul. 30 at 6:21 AM
$PCVX Prasad gone is a positive for PCVX. Go time 🚀🚀
0 · Reply
peterb030
peterb030 Jul. 17 at 2:52 PM
$LAES oke now its looking better $NVTS up $0.01 🫣 $PCVX gonna be one to watch(allready in 36.02) $BBAI not selling
0 · Reply
peterb030
peterb030 Jul. 17 at 5:56 AM
$PCVX Wall Street’s Bullish Outlook: Triple-Digit Upside Potential Wall Street is overwhelmingly bullish on Vaxcyte. The company currently trades around $33.40, but analysts see significant upside over the next 12 months. Based on the average one-year price target provided by eight analysts, Vaxcyte’s fair value sits at $125.75, implying a potential upside of more than 276%. The high-end estimate reaches as far as $163.00, while the low-end remains above $65.00—still nearly double the current trading price.
0 · Reply
osvaldo
osvaldo Jul. 16 at 2:26 PM
$PCVX reckon the FDA will loose their positioning about vaccines while the PCVX trials still are developing to get some results, say 2h '26.
0 · Reply
JPB415
JPB415 Jul. 8 at 6:51 PM
$PCVX This damn stock always fizzle before closing
0 · Reply
Latest News on PCVX
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Aug 6, 2025, 4:05 PM EDT - 20 days ago

Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:01 PM EDT - 3 months ago

Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

May 1, 2025, 8:00 AM EDT - 4 months ago

Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

Vaccine stocks fall following FDA resignation

Mar 31, 2025, 6:21 PM EDT - 5 months ago

Vaccine stocks fall following FDA resignation

BNTX MRNA NVAX PFE PTCT XBI

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Mar 31, 2025, 3:39 PM EDT - 5 months ago

Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Mar 31, 2025, 8:56 AM EDT - 5 months ago

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Mar 31, 2025, 7:00 AM EDT - 5 months ago

Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Mar 30, 2025, 5:00 PM EDT - 5 months ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 3:26 AM EST - 6 months ago

Vaxcyte, Inc. (PCVX) Q4 2024 Earnings Call Transcript

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 4:01 PM EST - 6 months ago

Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Feb 12, 2025, 4:05 PM EST - 6 months ago

Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Feb 5, 2025, 8:00 AM EST - 7 months ago

Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Jan 30, 2025, 4:05 PM EST - 7 months ago

Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Jan 30, 2025, 11:51 AM EST - 7 months ago

Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

Jan 15, 2025, 7:15 AM EST - 8 months ago

Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy

PFE

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Dec 3, 2024, 8:00 AM EST - 9 months ago

Vaxcyte Initiates Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Nov 12, 2024, 7:30 AM EST - 10 months ago

Vaxcyte Provides Positive Regulatory Updates on VAX-31 Pediatric and Adult Programs

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 4:01 PM EST - 10 months ago

Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Sep 11, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Sep 8, 2024, 9:00 AM EDT - 1 year ago

Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 6, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Sep 6, 2024, 3:07 PM EDT - 1 year ago

Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Sep 6, 2024, 9:07 AM EDT - 1 year ago

Vaxcyte's stock dips after biotech completes $1.42 billion stock offering

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Sep 5, 2024, 1:22 AM EDT - 1 year ago

Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Sep 4, 2024, 11:58 PM EDT - 1 year ago

Vaxcyte Announces Pricing of $1.3 Billion Public Offering

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Sep 3, 2024, 4:01 PM EDT - 1 year ago

Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Sep 3, 2024, 10:48 AM EDT - 1 year ago

Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Sep 3, 2024, 10:10 AM EDT - 1 year ago

Vaxcyte stock soars 35% on promising VAX-31 vaccine trial results

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Sep 3, 2024, 9:24 AM EDT - 1 year ago

Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Sep 3, 2024, 8:51 AM EDT - 1 year ago

Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 3, 2024, 7:07 AM EDT - 1 year ago

Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Sep 2, 2024, 6:40 PM EDT - 1 year ago

Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older

Vaxcyte Appoints John Furey to Board of Directors

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Vaxcyte Appoints John Furey to Board of Directors

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Apr 2, 2024, 4:05 PM EDT - 1 year ago

Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Mar 4, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 12:32 AM EST - 1 year ago

Vaxcyte, Inc. (PCVX) Q4 2023 Earnings Call Transcript

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 27, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Feb 15, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 2, 2024, 6:39 PM EST - 1 year ago

Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 1 year ago

Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

Vaxcyte Announces Pricing of $750 Million Public Offering

Jan 30, 2024, 11:37 PM EST - 1 year ago

Vaxcyte Announces Pricing of $750 Million Public Offering

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Jan 29, 2024, 8:30 AM EST - 1 year ago

Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older

Vaxcyte Appoints Whitney Jones as Chief People Officer

Jan 16, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Appoints Whitney Jones as Chief People Officer

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

Jan 4, 2024, 4:01 PM EST - 1 year ago

Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Dec 4, 2023, 6:35 PM EST - 1 year ago

VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate

Vaxcyte Appoints Jacks Lee to Board of Directors

Nov 28, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Appoints Jacks Lee to Board of Directors

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Nov 27, 2023, 4:00 PM EST - 1 year ago

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Nov 9, 2023, 8:30 AM EST - 1 year ago

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

justiceforb_85
justiceforb_85 Aug. 8 at 1:00 AM
$PCVX look forward to VAX-31 entering the clinic. Company with significant cash reserve but timeline in long.
0 · Reply
OptionRunners
OptionRunners Aug. 7 at 3:05 PM
$PCVX Buyer of the December 19th $30 calls 1,000 times for $4.80-$4.90 Buying into this earnings sell off
0 · Reply
d_risk
d_risk Aug. 7 at 1:15 AM
$PCVX - Vaxcyte Inc. Common Stock - 10Q - Updated Risk Factors PCVX’s 10-Q risk update spotlights pipeline shifts with paused/discontinued candidates, intensified focus on VAX-31 Phase 3, expanded regulatory and manufacturing complexities, evolving ACIP guidelines, heightened financial losses, and new risks around data variability, AI use, cybersecurity, global trials, IP litigation, and ESG compliance—all amid a challenging competitive and policy landscape. #Biotechnology #Cybersecurity #FinancialRisk #RegulatoryCompliance #VaccineDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/PCVX/10-Q/2025-08-06
0 · Reply
joe77w
joe77w Aug. 1 at 3:10 AM
$STRO $PCVX $EXEL worth more dead than alice, STRO worth at least 2.5usd if liquidate imo
1 · Reply
mmqwerty00
mmqwerty00 Aug. 1 at 2:26 AM
$STRO Jane needs to not be a hero. Preclinical molecules with no Phase 1 expansion data until 2027 - spread way too thin. Need to use her head, announce "strategic alternatives" and the stock goes to $1.50 overnight. Stick a 250M asking price on it - go to $PCVX or $EXEL and try and sell the whole thing - they give you 180M-200M in current market, you say thanks and call it a day. Puts stock around 2-2.50/share. The dilution that will eventually be needed to do anything of value would be catastrophic. Know the hand you are holding. Trying to take 3 preclinical molecules into clinic with just 18-24 months of cash, your stock price at all time lows and a biotech market where trying to use meaningful capital will get you demolished? Literally would be insanity. Lets hope they are smarter than this dumb guy who can see this clearly and figure it out
0 · Reply
Icarus81
Icarus81 Jul. 30 at 6:21 AM
$PCVX Prasad gone is a positive for PCVX. Go time 🚀🚀
0 · Reply
peterb030
peterb030 Jul. 17 at 2:52 PM
$LAES oke now its looking better $NVTS up $0.01 🫣 $PCVX gonna be one to watch(allready in 36.02) $BBAI not selling
0 · Reply
peterb030
peterb030 Jul. 17 at 5:56 AM
$PCVX Wall Street’s Bullish Outlook: Triple-Digit Upside Potential Wall Street is overwhelmingly bullish on Vaxcyte. The company currently trades around $33.40, but analysts see significant upside over the next 12 months. Based on the average one-year price target provided by eight analysts, Vaxcyte’s fair value sits at $125.75, implying a potential upside of more than 276%. The high-end estimate reaches as far as $163.00, while the low-end remains above $65.00—still nearly double the current trading price.
0 · Reply
osvaldo
osvaldo Jul. 16 at 2:26 PM
$PCVX reckon the FDA will loose their positioning about vaccines while the PCVX trials still are developing to get some results, say 2h '26.
0 · Reply
JPB415
JPB415 Jul. 8 at 6:51 PM
$PCVX This damn stock always fizzle before closing
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 7 at 9:25 AM
$PCVX Brilliant piece that captures PCVX's situation perfectly. So if you want to update your understanding of PCVX or get to know PCVX better, this is essential reading. https://beyondspx.com/article/vaxcyte-s-high-fidelity-approach-unlocking-broad-spectrum-vaccine-potential-pcvx
1 · Reply
BioTechHealthX
BioTechHealthX Jun. 22 at 4:17 AM
$PCVX Discover how Vaxcyte’s revolutionary vaccine technology and massive market potential make PCVX one of the best stocks of 2025. https://biotechhealthx.com/biotech-news/vaxcyte-pcvx-could-be-the-next-biotech-giant-in-the-vaccine-industry/
0 · Reply
bulldoglane
bulldoglane Jun. 9 at 1:39 PM
$PCVX 40 coming anytime
0 · Reply
BIG_STOCKY
BIG_STOCKY Jun. 9 at 12:58 PM
$PCVX IS THIS DAMN THING EVER GOING TO HIT $40 AGAIN?
0 · Reply
swingingtech
swingingtech Jun. 5 at 12:58 PM
$ESML $PCVX $NRIX $MNKD https://wallstreetwaves.com/esml-projected-to-reach-48-based-on-mathematical-analysis/
0 · Reply
Washingtonstate
Washingtonstate Jun. 2 at 7:49 PM
$PCVX
0 · Reply
theCATALYST
theCATALYST May. 29 at 8:12 PM
$ARVN $PCVX $SLDB +12% / +1% / +7%
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 27 at 6:49 PM
Biopharma investing can be brutal. If anyone can explain $TVTX as the AdCom was announced on 5/15/25 as was the PDUFA extension at $BHVN? $PCVX $VERA $RVMD there appears nothing...then why?
1 · Reply
theCATALYST
theCATALYST May. 27 at 3:56 PM
Re-added and/or added more in my Roth; $ARVN $PCVX $SLDB
0 · Reply
Stmkr
Stmkr May. 24 at 4:43 AM
$CDTX $PCVX is currently valued at around $4B for its pneumococcal vaccine, which btw faces fierce competition. Imagine the value of $CDTX after a positive ph2b next month! (1) CD388 will be the ONLY product that offers UNIVERSAL protection against ALL flu strains and in ALL patients (even those that can not ammount a proper immune response to vaccine) (2) CD388 is NOT a vaccine, but a long-acting (single dose for whole season) antiviral (3) I dont know if/when another flu pandemic is coming, but you can all guess what will happen to CDTX price in such a scenario. Even just for pandemic preparedness I see a high potential for good revenue. Obviously, CDTX will need cash for a ph3 (easy after a positive ph2b). CDTX also has an oncology pipeline (currently paused, but easily to be revived after a positive ph2b for flu)
0 · Reply
approved_13
approved_13 May. 20 at 4:45 PM
$PCVX
0 · Reply
Dr_Stoxx
Dr_Stoxx May. 20 at 4:35 PM
Some in our LIVE ROOM are long $PCVX. I had shares myself but sold most on the pop. If this base breaks out, it could get really interesting.
0 · Reply